We’re officially conference-weary after running around the San Diego Convention Center for four days of ADA briefings, sessions, meet-ups and expo booth visits. We lugged home loads of material that will surely keep us post-happy here at the ‘Mine for weeks. So what was super-new and hot? Spoiler Alert: Not all that much this year.
Our overall impression was that a lot of cool technologies we’ve already seen are stuck in the holding pen while…
Read more »
Health professionals reportedly are receiving letters this week alerting them to an FDA warning just issued about risks of thyroid cancer and pancreatitis associated with the popular type 2 diabetes drug liraglutide (Victoza). Yikes!
According to MSM reports, the evidence was found in mice, and it’s unclear if the serious risks translate to humans — but there was enough concern to issue the follow warning:
“Clinical trials have shown more cases of pancreatitis with liraglutide…
Read more »
By
AmyT on
November 3, 2010
Why is affordable generic insulin not available to patients in the US? Mainly because the big manufacturers have a stronghold on the patents for this complicated “biologic” drug. But now it seems Big Pharma itself may be presenting a nice alternative.
What I’m talking about is Pfizer’s new attempt to enter the injectable insulin market (less risky than their Exubera flop!) Pfizer and Biocon, a biopharmaceutical company in India, recently announced a multimillion dollar partnership…
Read more »
